Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Taiwan / NCT07114640
Starting soon Phase 3

The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial

NCT07114640 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Far Eastern Memorial Hospital
Phase
Phase 3
Started
2025-08-07
Last updated
2025-08-11

Condition(s) studied

Urinary Bladder, Overactive

Investigational drug(s) / intervention(s)

Mirabegron 25mg →Solifenacin 5 mg →Tolterodine 4 mg →Oxybutynin ER 5 mg →

Mirabegron 25mg: Taking 25 mg mirabegron in the nighttime

Solifenacin 5 mg: Taking 5 mg solifenacin in the nighttime

Tolterodine 4 mg: Taking 5 mg tolterodine in the nighttime

Oxybutynin ER 5 mg: Taking 5 mg oxybutynin ER in the nighttime

Study summary

The optimal medication for women with nocturia remains uncertain. This clinical trial aimed to determine the most effective medication for women with overactive bladder and nocturia. Its primary objectives were to answer the following questions:

Which medication is most effective for women with nocturia? Which medication has the least effect on heart rate variability in women with nocturia?

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * \>18 years old. * female patients with overactive bladder syndrome Exclusion Criteria: * Clinically significant dysuria (inability to urinate, difficulty urinating). * Severe stress urinary incontinence (urinary incontinence caused by coughing). * Mixed urinary incontinence mainly caused by stress urinary incontinence (urinary incontinence caused by coughing as the main symptom). * Contraindications to antimuscarinic drugs or adrenergic receptor agonists.

Primary outcome measure(s)

  • Improvement of overactive bladder symptoms — 12 weeks
    Comparisons of the changes of overactive bladder symptom score between groups

Trial sites (1)

FacilityCityRegionStatus
Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, Banqiao District New Taipei

More Far Eastern Memorial Hospital trials in Taiwan

Effect of Single Facial Acupuncture on Dermal Structure and Appearance Satisfaction Recruiting
Treatment Efficacy for Overactive Bladder: Comparing Education, Biofeedback, and Nerve Stimulation Starting soon
Maternal Methyl-Nutrient Status and Infant Neurodevelopment Study Recruiting
A Multi-center Cardiac PYP Scan Registry in Taiwan Recruiting
Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis Recruiting

Other trials for the same condition

Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder Recruiting
Treatment Efficacy for Overactive Bladder: Comparing Education, Biofeedback, and Nerve Stimulation Starting soon
Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity Recruiting
Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07114640 on ClinicalTrials.gov ↗ ← All trials in Taiwan